Revenue Cycle Advisory for Oncology.

Why Revenue Cycle Management Is Different for Oncology

Medical and radiation oncology practices carry extraordinary working-capital exposure: a single chemotherapy, immunotherapy, or biologic infusion regimen involves $10,000 to $50,000+ in buy-and-bill drug inventory where a single authorization, J-code unit, or wastage modifier error wipes out the entire margin of dozens of visits.

Oncology coding requires flawless hierarchy application across chemotherapy and complex biologic infusion administration (96401–96417), therapeutic/hydration concurrent vs. sequential pushes (96360–96379), HCPCS J-code/Q-code milligram-to-billable-unit math, National Drug Code (NDC) 5-4-2 formatting, and mandatory JW/JZ single-dose vial wastage modifiers.

• Chemotherapy and biologic infusion hierarchy coding (initial, sequential, concurrent, and prolonged infusion start/stop times)
• HCPCS J-code/Q-code billable unit conversion, 11-digit 5-4-2 NDC matching, and mandatory JW/JZ drug wastage modifiers
• Radiation oncology treatment planning, IMRT/SBRT/IGRT delivery (77261–77427), and weekly treatment management coding
• NCCN Compendium clinical appeal packages for off-label and precision-oncology biomarker-driven therapies

Prior Authorization, Medical Necessity & Denial Patterns in Oncology

Regimen-level prior authorizations must cover every antineoplastic agent, supportive-care colony-stimulating factor, anti-emetic, and diagnostic staging scan—and must be re-verified immediately whenever an oncologist adjusts dosage or switches lines of therapy.

Catastrophic oncology losses stem from CARC 197 (regimen/dose change without updated prior auth), CARC 50 (off-label NCCN compendium medical necessity denials), NDC/J-code unit conversion errors, and uncollected Medicare dual-eligible/patient co-insurance without foundation copay assistance.

• Front-end eligibility and benefit verification tied directly to scheduled CPT/HCPCS procedure codes and site-of-service POS indicators
• Automated tracking of payer-specific prior authorization validity windows, unit thresholds, and peer-to-peer clinical escalation timelines
• Root-cause categorization of CARC 50 (medical necessity), CARC 97 (bundling/inclusive service), CARC 197 (missing precertification), and CARC 4/16 (modifier/claim data errors)
• Contractual underpayment variance auditing against Medicare Physician Fee Schedule (MPFS), ASC payment rates, and commercial payer fee schedules

Important KPIs, Benchmarks & A/R Economics for Oncology Groups

In community oncology and hospital outpatient infusion centers, eliminating J-code/NDC unit errors and tightening regimen prior authorization protects millions of dollars in at-risk drug inventory.

Synchronizing oncology EHRs (Flatiron OncoEMR, Elekta MOSAIQ, Varian ARIA, Epic Beacon) with Automated Dispensing Cabinets (Lynx, Pyxis) and PM billing systems is critical to prevent drug-unit and administration hierarchy leaks.

In-House vs. Outsourced Oncology Billing: What to Evaluate in an RCM Partner

Deciding whether to run oncology billing internally, operate a hybrid model, or outsource to a specialty RCM company requires looking past headline percentage fees. A billing vendor charging 4% that leaves 6% of net collectible revenue on the table through unappealed CARC 97/50 denials or unworked >90-day A/R costs far more than a disciplined internal or specialty-calibrated operation.

RCM Advisory Partners helps organizations benchmark their current operation before negotiating with vendors, and structures rigorous evaluation criteria when an external partner is warranted.

• Vial-to-claim reconciliation between pharmacy dispensing logs (MAR) and billed J-code/NDC units
• Pre-infusion financial clearance, regimen-change re-authorization triggers, and foundation copay enrollment
• Quarterly ASP + percentage fee schedule updates and underwater drug contract alerting
• Audit of infusion start/stop time documentation and initial-service hierarchy selection
• Verify certified coder proficiency in oncology CPT/HCPCS hierarchies, NCCI bundling edits, and Medicare LCDs
• Audit true net collection yield against contracted oncology fee schedules rather than blended gross adjustments
• Require transparent workqueue visibility on >60 and >90 day A/R and clinical appeal overturn rates

30/60/90-Day Oncology Revenue Cycle Diagnostic & Optimization Plan

Our advisory engagements translate oncology claim and remittance data into a prioritized 90-day execution roadmap:

1. 01
   Days 1–30: Specialty Claim Audit, Coding Review & Fee Schedule Reconciliation

   Audit a statistically valid sample of paid, denied, and zero-pay oncology claims across top commercial and Medicare payers; benchmark CPT/modifier distribution and identify immediate underpayment and denial recovery opportunities.

2. 02
   Days 31–60: Prior Authorization, Scrubber Edit & EHR Template Remediation

   Reconfigure front-end authorization matrices, clinical documentation templates, and clearinghouse NCCI/LCD pre-bill edits to stop preventable denials before 837 submission.

3. 03
   Days 61–90: Aged A/R Recovery, Payer Escalation & Vendor SLA Governance

   Deploy structured appeal playbooks for high-value surgical, diagnostic, or infusion claims, and establish monthly KPI scorecards holding internal leads or external billing partners accountable.